Semaglutide
Semaglutide (Compounded GLP-1 Receptor Agonist)
Semaglutide is the active ingredient in Ozempic and Wegovy — the medications that sparked the GLP-1 weight loss revolution. It's a modified version of a hormone your gut naturally produces called GLP-1 (glucagon-like peptide-1). When you eat, your body releases GLP-1 to signal your brain that you're full.
Why does this matter?
Semaglutide matters because it gives people a real, physician-guided option for Chronic weight management for adults with BMI ≥30 and Average weight loss of 15% body weight in clinical trials. This page helps readers understand what it may do, what the tradeoffs look like, and why getting it through GobyMeds is different from buying anonymous products online.
Molecular weight
4,113.58 g/mol
Molecular formula
C₁₈₇H₂₉₁N₄₅O₅₉
Amino acid count
31
Availability
Available Now
Sequence / structure
31 amino acids (modified human GLP-1 analog)
Other names
Semaglutide, Ozempic (brand, diabetes indication), Wegovy (brand, weight management indication), Rybelsus (brand, oral form), Compounded semaglutide, GLP-1 receptor agonist
Status
FDA-approved active ingredient
Semaglutide is the active ingredient in Ozempic and Wegovy — the medications that sparked the GLP-1 weight loss revolution. It's a modified version of a hormone your gut naturally produces called GLP-1 (glucagon-like peptide-1). When you eat, your body releases GLP-1 to signal your brain that you're full. Semaglutide does the same thing, but much more powerfully and for much longer (one injection lasts a full week vs the natural hormone's 2-minute lifespan). The result? Dramatically reduced appetite, less food noise in your head, and significant weight loss — clinical trials showed average losses of 15% body weight. Compounded semaglutide is available through GobyMeds at a fraction of brand-name prices, prescribed by licensed physicians and produced by FDA-registered compounding pharmacies.
The quick version before the deep dive
- •People usually talk about Semaglutide for Chronic weight management for adults with BMI ≥30 and Average weight loss of 15% body weight in clinical trials.
- •Average weight loss of 15% body weight in clinical trials (STEP 1).
- •Activates GLP-1 receptors in your brain's appetite center (the part of your brain that helps control hunger), dramatically reducing hunger signals. Most patients describe it as "the food noise just... stops".
- •Slows how fast food leaves your stomach (how fast food leaves your stomach), so you feel satisfied after smaller meals and stay full for hours.
Deep Dive: Mechanism of Action +
Turns Down the Hunger — Activates GLP-1 receptors in your brain's appetite center (hypothalamus), dramatically reducing hunger signals. Most patients describe it as "the food noise just... stops"
Keeps You Full Longer — Slows gastric emptying (how fast food leaves your stomach), so you feel satisfied after smaller meals and stay full for hours
Blood Sugar Control — Tells your pancreas to release more insulin when blood sugar rises (glucose-dependent, so low risk of dangerous blood sugar drops)
Stops Sugar Overproduction — Reduces glucagon, a hormone that tells your liver to dump sugar into your blood
Protects Your Heart — Reduces inflammation in blood vessels, improves cholesterol, and lowers blood pressure — benefits that go beyond just weight loss
May Quiet Cravings — Emerging research suggests semaglutide affects dopamine reward pathways, potentially reducing cravings for food, alcohol, and other compulsive behaviors
Where people usually see it discussed
Weight Management (Primary Use) +
- Chronic weight management for adults with BMI ≥30 (or ≥27 with weight-related conditions)
- Average weight loss of 15% body weight in clinical trials (STEP 1)
- Long-term weight maintenance when combined with lifestyle changes
- Visceral fat reduction (the dangerous belly fat around organs)
Type 2 Diabetes +
- A1C reduction (typically 1.5-2.0 percentage points)
- Blood sugar stabilization throughout the day
- Reduced need for other diabetes medications
- Some patients achieve diabetes remission
Cardiovascular Protection +
- 20% reduction in heart attack, stroke, and cardiovascular death (SELECT trial)
- Blood pressure improvement
- LDL cholesterol reduction
- These benefits occur regardless of diabetes status
Emerging Research +
- Chronic kidney disease protection (FLOW trial: 24% reduction in major kidney events)
- Non-alcoholic fatty liver disease (NAFLD/NASH) — significant liver fat reduction
- Obstructive sleep apnea improvement
- Addiction behavior reduction (alcohol use, binge eating — research ongoing)
- Alzheimer's disease (clinical trials underway)
Formal evidence and study snapshots
Deep Dive: Clinical Trials +
STEP 1 (Wegovy)
Phase IIIWeight loss in obesity
14.9% body weight loss vs 2.4% placebo over 68 weeks
STEP 2
Phase IIIWeight loss in T2D
9.6% weight loss + significant A1C reduction
STEP 3
Phase IIIWeight loss + behavioral therapy
16% weight loss with intensive behavioral support
STEP 5
Phase IIILong-term maintenance
Sustained weight loss over 2 years of continued treatment
SELECT
Phase IIICardiovascular outcomes
20% reduction in major cardiovascular events (heart attack, stroke, CV death)
FLOW
Phase IIIKidney disease
24% reduction in major kidney events in T2D patients with CKD
SUSTAIN 6
Phase IIICV safety in diabetes
26% reduction in major cardiovascular events
What the current safety discussion looks like
- ✓FDA-approved with extensive safety data from trials involving 10,000+ participants
- ✓Most common side effects (GI): Nausea (most common, especially early on — improves with time), diarrhea, constipation, vomiting. These are dose-related and managed by starting low and titrating slowly.
- ✓Less common: Headache, fatigue, dizziness, injection site reactions (mild)
- ✓Rare but serious: Pancreatitis (uncommon), gallbladder issues (gallstones can occur with rapid weight loss), thyroid C-cell tumors (seen in rodents at extreme doses, not confirmed in humans — boxed warning is precautionary)
- ✓Contraindications: Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe GI disease (gastroparesis), pregnancy/breastfeeding
- ✓Muscle mass: Some lean mass loss occurs with any significant weight loss — resistance training and high protein intake (0.7-1g per pound body weight) are strongly recommended
- ✓Compounded semaglutide safety: Same active ingredient as branded Ozempic/Wegovy. GobyMeds sources only from FDA-registered, cGMP-compliant 503A compounding pharmacies with third-party testing
How the status timeline currently reads
2017
Semaglutide (Ozempic) FDA-approved for type 2 diabetes
2021
Semaglutide (Wegovy) FDA-approved for chronic weight management
2024-2026
Compounded semaglutide available through 503A pharmacies during shortage period
Present
Available now through GobyMeds — compounded semaglutide starting at $299/month
How dosing is usually described
Standard Titration Schedule (Weekly SubQ Injection)
Month 1: 0.25 mg/week (getting your body used to it) Month 2: 0.5 mg/week (appetite effects start) Month 3: 1.0 mg/week (full therapeutic effect for most) Month 4+: 1.0-2.4 mg/week (adjusted based on your response and goals)
Injection Tips
Once weekly, same day each week (pick a day and stick with it) Inject SubQ into abdomen, thigh, or upper arm — rotate sites Can be done any time of day, with or without food Room temperature injection is more comfortable than cold
Managing Side Effects
Start low, go slow — the #1 way to minimize nausea Eat smaller meals — your appetite will naturally decrease Stay hydrated — drink plenty of water, especially first few weeks Protein first — prioritize protein at every meal to preserve muscle If nauseous: Bland foods, ginger, smaller portions. It typically improves within 2-4 weeks
Prescribed by licensed providers. Individual treatment plans vary.
The citations behind the page
Deep Dive: Key Research Papers +
- 1
Wilding JPH, et al.*. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." New England Journal of Medicine 2021.
- 2
Lincoff AM, et al.*. "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." New England Journal of Medicine 2023.
- 3
Perkovic V, et al.*. "Effects of semaglutide on chronic kidney disease (FLOW)." New England Journal of Medicine 2024.
- 4
Davies M, et al.*. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." The Lancet 2021.
- 5
Rubino DM, et al.*. "Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity (STEP 8)." JAMA 2022.
- 6
Drucker DJ.*. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 2018.
Common questions about Semaglutide
What is Semaglutide? +
Semaglutide is Semaglutide (Compounded GLP-1 Receptor Agonist), a treatment currently available through licensed prescribing and compounding pathways.
What is Semaglutide commonly used for? +
Semaglutide is most often discussed for Chronic weight management for adults with BMI ≥30, Average weight loss of 15% body weight in clinical trials, Long-term weight maintenance when combined with lifestyle changes, and Visceral fat reduction.
Which category does Semaglutide belong to? +
Semaglutide is grouped in this library under Weight and Metabolic.
How many amino acids are in Semaglutide? +
Semaglutide is presented here as a 31-amino-acid peptide or peptide analog based on the source research and naming conventions.
What is the sequence or structure note for Semaglutide? +
31 amino acids (modified human GLP-1 analog).
What research applications are most associated with Semaglutide? +
Chronic weight management for adults with BMI ≥30, Average weight loss of 15% body weight in clinical trials, Long-term weight maintenance when combined with lifestyle changes, and Visceral fat reduction
How is Semaglutide described as working in the current research? +
Activates GLP-1 receptors in your brain's appetite center (the part of your brain that helps control hunger), dramatically reducing hunger signals. Most patients describe it as "the food noise just... stops". Slows how fast food leaves your stomach (how fast food leaves your stomach), so you feel satisfied after smaller meals and stay full for hours.
How is Semaglutide usually discussed in protocols or treatment plans? +
Semaglutide is most often described with standard titration schedule and injection tips protocols in the source material.
What does the safety discussion say about Semaglutide? +
FDA-approved with extensive safety data from trials involving 10,000+ participants Most common side effects (GI): Nausea (most common, especially early on — improves with time), diarrhea, constipation, vomiting. These are dose-related and managed by starting low and titrating slowly.
Continue the comparison
Tirzepatide
Tirzepatide is the next evolution in GLP-1 weight loss medications — and it's even more effective than semaglutide. While semaglutide activates one appetite hormone receptor (GLP-1), tirzepatide activates TWO: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action is why clinical trials showed up to 22.
MOTS-c
MOTS-c is a peptide people usually talk about for Obesity and Type 2 diabetes / insulin resistance. It is still in the FDA review process, so people are watching both the research and the access question closely.
Sermorelin
Sermorelin is a synthetic version of the first 29 amino acids of your body's natural growth hormone-releasing hormone (GHRH). Instead of replacing growth hormone directly (like HGH injections), Sermorelin tells your pituitary gland to produce more of its own growth hormone naturally. Think of it as turning up the volume on a system your body already has — it preserves your body's natural feedback mechanisms so you get the benefits of higher growth hormone without the risks of flooding your system with external HGH.
Get Semaglutide from GobyMeds
Physician-guided care, pharmacy fulfillment, and a legitimate treatment path that starts with real medical review instead of anonymous sourcing.
Starting at $99/m
Available through GobyMeds for readers who are ready to move from research into a real care conversation.